12,372 trials
Myelodysplastic Syndromes
Primary: Kaplan-Meier Estimates for Median Time to Death From Any Cause — 24.46; 15.02 months — p=0.0001
Hepatitis B
Primary: Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24 — -4.48; -3.40 log10 copies/mL — p=<0.0001
Child Development
Primary: Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III) — 86.5; 87.4 Scores on a scale — p=0.59
Hypercholesterolemia
Primary: Number of Participants With Adverse Events and Adverse Reactions — 143; 36 Participants
Coccidioidomycosis
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A — 5; 3…
Manic or Mixed Episode Associated With Bipolar I Disorder
Primary: Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only — -3.0 units on a scale
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8 — -13.63; -14.30 units on scale — p=0.243
Osteogenesis Imperfecta
Primary: Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population — 7.592; 16.159 Percent Change — p=<0.0001
Excessive Daytime Sleepiness · Narcolepsy · Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
Primary: Number of Responders to the Patient Global Impression of Change (PGI-C) Ratings — 241 Participants
Influenza
Primary: Geometric Mean Titers (GMTs), by Vaccine Lots — 566; 518; 513; 352 Titers
Low Back Pain
Primary: Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12. — -2.9…
Psoriasis
Primary: Number of Patients Who Achieve a Physician Global Assessment (PGA) Score of Minimal (1) or Clear (0) — 138 participants — p=0.05
Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Primary: Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan — -1.7 kg — p=<0.001
Migraine
Primary: Participants With Elimination of Nausea at 2 Hours Postdose — 130; 57; 55; 35 Participants
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15 — 9.31; 9.31; -2.54; -1.66 Score on a scale — p=<0.001